ABSTRACT
Device embolization is a rare major complication of atrial septal defect percutaneous closures which requires surgical management if noninvasive retrieval fails. We report a symptomatic delayed embolization of an Amplatzer septal occluder device into the left ventricle outflow tract tangled with the mitral valve, complicated with ventricular arrhythmias and cardiac tamponade during percutaneous retrieval attempt. Emergent surgical treatment was performed, requiring a combined approach through the right atrium and the aorta for surgical removal.
Subject(s)
Cardiac Surgical Procedures/methods , Device Removal/methods , Embolism/etiology , Embolism/surgery , Foreign-Body Migration/surgery , Heart Ventricles , Mitral Valve/surgery , Septal Occluder Device/adverse effects , Aged , Aorta , Arrhythmias, Cardiac/etiology , Cardiac Tamponade/etiology , Female , Heart Atria , Humans , Treatment OutcomeABSTRACT
Aims: We aimed to determine whether treatment with sildenafil improves outcomes of patients with persistent pulmonary hypertension (PH) after correction of valvular heart disease (VHD). Methods and results: The sildenafil for improving outcomes after valvular correction (SIOVAC) study was a multricentric, randomized, parallel, and placebo-controlled trial that enrolled stable adults with mean pulmonary artery pressure ≥ 30 mmHg who had undergone a successful valve replacement or repair procedure at least 1 year before inclusion. We assigned 200 patients to receive sildenafil (40 mg three times daily, n = 104) or placebo (n = 96) for 6 months. The primary endpoint was the composite clinical score combining death, hospital admission for heart failure (HF), change in functional class, and patient global self-assessment. Only 27 patients receiving sildenafil improved their composite clinical score, as compared with 44 patients receiving placebo; in contrast 33 patients in the sildenafil group worsened their composite score, as compared with 14 in the placebo group [odds ratio 0.39; 95% confidence interval (CI) 0.22-0.67; P < 0.001]. The Kaplan-Meier estimates for survival without admission due to HF were 0.76 and 0.86 in the sildenafil and placebo groups, respectively (hazard ratio 2.0, 95% CI = 1.0-4.0; log-rank P = 0.044). Changes in 6-min walk test distance, natriuretic peptides, and Doppler-derived systolic pulmonary pressure were similar in both groups. Conclusion: Treatment with sildenafil in patients with persistent PH after successfully corrected VHD is associated to worse clinical outcomes than placebo. Off-label usage of sildenafil for treating this source of left heart disease PH should be avoided. The trial is registered with ClinicalTrials.gov, number NCT00862043.
Subject(s)
Heart Valve Diseases/complications , Hypertension, Pulmonary/drug therapy , Sildenafil Citrate/therapeutic use , Aged , Double-Blind Method , Female , Heart Failure/epidemiology , Heart Valve Diseases/epidemiology , Heart Valve Diseases/mortality , Humans , Hypertension, Pulmonary/physiopathology , Male , Placebos/administration & dosage , Pulmonary Wedge Pressure/drug effects , Sildenafil Citrate/administration & dosage , Treatment Outcome , Vasodilator Agents/therapeutic useABSTRACT
BACKGROUND: The MitraClip® system is a percutaneous treatment for mitral regurgitation (MR) that has shown promising results in patients who are inoperable or at high risk for mitral surgery. Data on the efficacy of the system over optimal medical therapy, above all in patients with functional MR, are scarce. The study aim was to assess the effect of MitraClip on the survival of patients with moderate/severe or severe MR compared to medical therapy, using meta-analytical techniques. METHODS: Independently, reviewers searched electronically for relevant articles based on predefined criteria and end-points. Only articles with a comparison between MitraClip and conservative therapy were included. Standard meta-analysis techniques were used. The primary outcomes were 30-day and one-year mortalities. RESULTS: Five observational reports were included that enrolled a total of 1,271 patients: 720 patients underwent percutaneous mitral valve repair (PMVR) with the MitraClip device, and 551 were managed conservatively. A total of 49 all-cause mortality events was reported at 30 days: 3.05% (22/720) in the PMVR arm, and 4.90% (27/510) in the conservative group, with no significant differences in all-cause mortality (OR 0.64; 95% CI 0.36-1.14). A total of 269 all-cause mortality events at one year was reported: 15.14% (109/720) in the PMVR arm, and 29.04% (160/551) in the conservative group. A significant difference favoring PMVR with the MitraClip system over medical therapy alone was observed (OR 0.44; 95% CI 0.30-0.64, p <0.0001). Neither significance between study heterogeneity (p = 0.18) nor publication bias was detected (p = 0.3). CONCLUSIONS: PMVR with the MitraClip system may be associated with an improvement in one-year survival compared to stand-alone medical management.
Subject(s)
Endovascular Procedures/instrumentation , Mitral Valve Insufficiency/therapy , Mitral Valve/surgery , Conservative Treatment , Humans , Mitral Valve Insufficiency/mortalityABSTRACT
We present the case of a high-risk patient with symptomatic severe mitral regurgitation following a surgical annuloplasty ring. An inverted aortic Edwards Sapien 3 bioprosthesis (Edwards Lifesciences, Irvine, CA) was successfully implanted through a transapical approach inside the previously implanted annuloplasty ring.
Subject(s)
Bioprosthesis , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis , Mitral Valve Annuloplasty/methods , Mitral Valve Insufficiency/surgery , Mitral Valve/surgery , Reoperation/methods , Aged , Heart Valve Prosthesis Implantation/instrumentation , Humans , Male , Mitral Valve Annuloplasty/instrumentation , Recurrence , Reoperation/instrumentationABSTRACT
Aortic regurgitation due to valve injury after blunt chest trauma is a rare condition that may be caused by leaflet or commissural rupture, aortic dissection, or a combination of both. The case is presented of a 48-year-old male patient with an aortic dissection and aortic valve commissural detachment and massive aortic regurgitation after a 12-meter vertical free fall and secondary thoracic blunt trauma. The aortic root tear and dissection was repaired with a continuous polypropylene 5/0 suture and subcommissural annuloplasty that restored the aortic valve geometry and resulted in a normally functioning aortic valve.
Subject(s)
Aortic Dissection/surgery , Aortic Valve Insufficiency/surgery , Aortic Valve/injuries , Aortic Valve/surgery , Thoracic Injuries/complications , Wounds, Nonpenetrating/complications , Accidental Falls , Aortic Dissection/etiology , Aortic Valve Insufficiency/etiology , Humans , Male , Middle AgedABSTRACT
Background To evaluate the influence of subclinical hypothyroidism (SCH) on the development of postoperative atrial fibrillation (AF) in patients undergoing aortic valve replacement surgery with extracorporeal circulation. Methods A prospective study in a tertiary hospital between July 2005 and December 2013 in which all patients undergoing aortic valve replacement with no other valve surgery were consecutively included. Patients who were in preoperative sinus rhythm were selected and they underwent thyroxine (T4) and thyroid-stimulating hormone determination in the month before surgery. Postoperative AF was defined as the development of AF during hospital admittance. Descriptive analysis and binary logistic regression were performed for the target variable. Results A total of 467 patients were studied, with 35 cases of SCH. The incidence of postoperative AF was 57% in the group with SCH versus 30.3% (p = 0.001) in the group without hypothyroidism, without significant differences in other postoperative complications. In the logistic regression analysis, the independent predictors of postoperative AF were SCH, age, and aortic clamping time. SCH multiplies the odds ratio of postoperative AF by 3.14 (95% confidence interval: 1.24-7.96). Conclusion SCH behaves like a risk factor for the development of postoperative AF in patients undergoing aortic valve replacement with extracorporeal circulation. Other studies are needed to determine whether preoperative T4 replacement therapy and/or more aggressive AF prophylaxis can prevent this complication in patients undergoing aortic valve replacement.
Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Atrial Fibrillation/epidemiology , Heart Valve Prosthesis Implantation/adverse effects , Hypothyroidism/etiology , Aged , Aged, 80 and over , Aortic Valve/diagnostic imaging , Aortic Valve/physiopathology , Aortic Valve Stenosis/diagnostic imaging , Aortic Valve Stenosis/epidemiology , Aortic Valve Stenosis/physiopathology , Asymptomatic Diseases , Atrial Fibrillation/diagnosis , Female , Heart Valve Prosthesis Implantation/instrumentation , Humans , Hypothyroidism/diagnosis , Incidence , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Prevalence , Prospective Studies , Risk Assessment , Risk Factors , Spain/epidemiology , Tertiary Care Centers , Time Factors , Treatment OutcomeABSTRACT
We report a case of transapical mitral valve-in-valve implantation for a deteriorated bioprosthesis using the Edwards Sapien 3 prosthesis via the transapical approach. This case demonstrates the safety and feasibility of using the Edwards Sapien 3 prosthesis in treating degenerated bioprosthetic mitral valves.
Subject(s)
Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis , Mitral Valve Insufficiency/surgery , Mitral Valve/surgery , Aged, 80 and over , Bioprosthesis , Echocardiography, Transesophageal , Feasibility Studies , Female , Follow-Up Studies , Humans , Mitral Valve Insufficiency/diagnostic imaging , Prosthesis Failure , Risk , Treatment OutcomeABSTRACT
We describe a technique that implants a rigid tricuspid annuloplasty ring over a previously inserted flexible ring for the treatment of recurrent tricuspid regurgitation. This technique avoids the trauma associated with the excision of a flexible ring in patients with friable annular tissue.
Subject(s)
Bioprosthesis , Cardiac Valve Annuloplasty/instrumentation , Heart Valve Prosthesis Implantation/adverse effects , Mitral Valve Insufficiency/surgery , Tricuspid Valve Insufficiency/surgery , Aged , Cardiac Valve Annuloplasty/methods , Female , Follow-Up Studies , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation/methods , Humans , Mitral Valve Insufficiency/diagnostic imaging , Prosthesis Failure , Recurrence , Reoperation/methods , Risk Assessment , Sternotomy/methods , Treatment Outcome , Tricuspid Valve Insufficiency/diagnostic imaging , Tricuspid Valve Insufficiency/etiology , UltrasonographyABSTRACT
OBJECTIVE: Elevations of myocardial injury biomarkers after cardiac surgery without ablation of atrial fibrillation (AF) are related to perioperative myocardial ischemia and associated with an increased risk of mortality and cardiac events. However, there have not been any studies that examined the release of cardiac biomarkers after AF cryoablation procedures with concomitant cardiac surgery. The authors determined the levels of these biomarkers for 2 different procedures involving cryoablation and assessed their clinical implications. DESIGN: A prospective cohort study with cardiac surgical patients. SETTING: A tertiary care university hospital. PARTICIPANTS: One hundred fifty-two cardiac surgical patients. INTERVENTIONS: Patients underwent 1 of 2 different cryoablation approaches: the modified Cox-Maze (CM) III procedure (n = 63) or the isolated left atrial (LA) maze procedure (n = 89). Plasma levels of cardiac biomarkers were measured at 1, 6, 12, and 24 hours after surgery. Twenty-four-hour Holter monitoring was performed at 1 month and 1 year after surgery. MEASUREMENTS AND MAIN RESULTS: Both groups reached very high peak levels of CPK-MB (CM group, 368 ± 171.4 ng/mL and LA group, 203 ± 86.4 ng/mL) and troponin T (CM, 8 ± 4.5 ng/mL and LA, 3.4 ± 2.4 ng/mL). The CPK, CPK-MB, and troponin T levels were significantly higher in the modified CM group compared with the LA maze group. In the first 24 hours after surgery, the average CPK-MB and troponin T values were 78.2 ng/mL higher and 2.3 ng/mL higher, respectively, in the CM group compared with the LA group. In both groups, 79% of the patients remained free of AF at 12 months after surgery. CONCLUSIONS: Cryoablation in cardiac surgery causes the release of very high levels of myocardial injury biomarkers. The modified CM lesion causes a greater elevation of serum biomarker levels than the isolated LA maze procedure, but this increase does not seem to have an adverse effect on rhythm or overall outcome. Cryoablation is a safe and effective surgical treatment for AF.
Subject(s)
Atrial Fibrillation/surgery , Cardiac Surgical Procedures/methods , Cryosurgery/methods , Heart Injuries/surgery , Postoperative Complications/surgery , Aged , Amiodarone/therapeutic use , Anesthesia , Anti-Arrhythmia Agents/therapeutic use , Anticoagulants/therapeutic use , Biomarkers , Cardiac Surgical Procedures/adverse effects , Coronary Artery Bypass/adverse effects , Creatine Kinase, MB Form/blood , Cryosurgery/adverse effects , Electrocardiography, Ambulatory , Endpoint Determination , Female , Follow-Up Studies , Heart Injuries/diagnosis , Humans , Male , Middle Aged , Postoperative Complications/diagnosis , Prospective Studies , Treatment Outcome , Troponin T/bloodABSTRACT
Background The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. Methods and Results We analyzed long-term follow-up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32-44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18-26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow-up of 4.5 years, 91 deaths accounted for 4.21 higher-than-expected mortality in the age-matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance-either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six-month changes in the composite clinical score and in the 6-minute walk test distance were related to survival. Conclusions Persistent valvular heart disease-pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT00862043.
Subject(s)
Heart Valve Diseases , Heart Valve Prosthesis Implantation , Hypertension, Pulmonary , Long Term Adverse Effects , Postoperative Complications , Sildenafil Citrate/administration & dosage , Diabetes Mellitus/epidemiology , Double-Blind Method , Female , Heart Valve Diseases/physiopathology , Heart Valve Diseases/surgery , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/methods , Heart Valves/pathology , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/mortality , Long Term Adverse Effects/diagnosis , Long Term Adverse Effects/drug therapy , Long Term Adverse Effects/mortality , Male , Middle Aged , Organ Size , Phosphodiesterase 5 Inhibitors/administration & dosage , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/mortality , Postoperative Complications/physiopathology , Pulmonary Wedge Pressure , Risk Factors , Vascular ResistanceSubject(s)
Heart Neoplasms/diagnostic imaging , Hemangioma, Cavernous/diagnostic imaging , Adult , Echocardiography , Echocardiography, Transesophageal , Female , Heart Atria , Heart Neoplasms/pathology , Heart Neoplasms/surgery , Hemangioma, Cavernous/pathology , Hemangioma, Cavernous/surgery , Humans , Tomography, X-Ray ComputedABSTRACT
Cardiac fibromas are rare benign tumors predominantly diagnosed in children and teenagers. We report a 57-year-old male patient with class II dyspnea and angina. During electrocardiographic assessment, recurrent ventricular tachycardia was present and magnetic resonance imaging revealed a giant (12.5 × 5 × 4 cm) intramural left ventricular tumor compatible with cardiac fibroma. After surgical biopsy and histological confirmation, open-heart surgical resection was successfully performed. After nine months of follow up, the patient remains asymptomatic without evidence of ventricular tachycardia.
Subject(s)
Fibroma/surgery , Heart Neoplasms/surgery , Tachycardia, Ventricular/etiology , Cardiac Surgical Procedures , Echocardiography , Fibroma/complications , Fibroma/diagnosis , Heart Neoplasms/complications , Heart Neoplasms/diagnosis , Heart Ventricles , Humans , Hypertrophy, Left Ventricular/etiology , Magnetic Resonance Imaging , Male , Middle Aged , Mitral Valve Insufficiency/etiology , Treatment OutcomeABSTRACT
In non-rheumatic atrial fibrillation (AF), left atrial appendage (LAA) is thought to be the source of embolism in 90% of the strokes. Thus, as recent clinical trials have shown the non-inferiority of percutaneous LAA closure (LAAc) in comparison to medical treatment, and despite a IIb recommendation in the latest guidelines for concomitant surgical LAAc, we sought to investigate the beneficial effect of LAAc in the surgical population. A meta-analysis model was performed comparing studies including any cardiac surgery with or without concomitant surgical LAAc reporting stoke/embolic events and/or mortality, from inception to January 2019. Twenty-two studies (280 585 patients) were included in the model. Stroke/embolic events both in the perioperative period [relative risk (RR) 0.66, 95% confidence interval (CI) 0.53-0.82; P = 0.0001] and during follow-up of >2 years (RR 0.67, 95% CI 0.51-0.89; P < 0.005) were significantly reduced in patients who underwent surgical LAAc (RR 0.71, 95% CI 0.58-0.87; P = 0.001). Regarding the rate of preoperative AF, LAAc showed protective effect against stroke/embolic events in studies with >70% preoperative AF (RR 0.64, 95% CI 0.53-0.77; P < 0.00001) but no benefit in the studies with <30% of preoperative AF (RR 0.77, 95% CI 0.46-1.28; P = 0.31). Postoperative mortality was also significantly lower in surgical patients with LAAc at the mid- and long-term follow-up. (RR 0.72, 95% CI 0.67-0.78; P < 0.00001; I2 = 0%). Based on these findings, concomitant surgical LAAc is associated with lower rates of embolic events and stroke in the postoperative period in patients with preoperative AF and also improves postoperative mortality in the mid- and long-term follow-up.
Subject(s)
Atrial Appendage , Atrial Fibrillation , Cardiac Surgical Procedures , Embolism , Stroke , Atrial Appendage/surgery , Atrial Fibrillation/surgery , Cardiac Surgical Procedures/adverse effects , Humans , Stroke/epidemiology , Stroke/prevention & control , Treatment OutcomeABSTRACT
We report the case of a severe prosthetic aortic stenosis in a 61-year-old male patient with an aortic Mitroflow LF bioprosthesis (Sorin Group) at early (6 months) postoperative echocardiographic follow-up. At reintervention, we found significant stent deformation, asymmetric orientation of the posts, and subsequent central kinking and prolapse of one leaflet. Maldistribution of pledgeted mattress sutures over the flexible stent was found to be the origin of its permanent deformation. Simple technical preventive strategies of this previously unreported complication are suggested.
Subject(s)
Aortic Valve Stenosis/etiology , Aortic Valve Stenosis/surgery , Bioprosthesis/adverse effects , Heart Valve Prosthesis/adverse effects , Prosthesis Failure , Stents/adverse effects , Device Removal , Humans , Male , Middle AgedABSTRACT
Transcatheter valve implantation has become an alternative to open-heart conventional surgery in high-risk patients. We describe a new surgical technique that allows the implantation of a transcatheter valvular prosthesis through an open surgical approach to prevent the appearance of paravalvular leaks in patients with large native rings.
Subject(s)
Anastomotic Leak/prevention & control , Heart Valve Prosthesis Implantation/methods , Pulmonary Valve Insufficiency/surgery , Anastomotic Leak/diagnostic imaging , Heart Valve Prosthesis , Humans , Male , Middle Aged , Pulmonary Valve Insufficiency/diagnostic imaging , StentsABSTRACT
Surgery of both the ascending and descending aortic segments in the context of an acute aortic syndrome is one of the greatest challenges for the cardiac surgeon. In the case of surgery of the descending aorta, surgical risk increases due to the technical complexity, the required aggressive approach and because surgical indication is usually established as a result of complications and therefore involves, almost always, critically ill patients. The aging of the population is causing such surgery to be considered in an increasing number of octogenarians. The present review analyzes the available scientific evidence on the surgical indications and outcomes of these complex procedures in this population, particularly in the emergent scenario. Ascending and descending thoracic aortic diseases are reviewed separately, and the role of both the current risk scores and frailty assessments are comprehensively discussed.
ABSTRACT
Aortic valve replacement (AVR) is the treatment of choice for aortic valve disease, with excellent results reported in the short- and long-term follow-up. Due to the increasing number of patient comorbidities and older age, various technical alternatives have been developed such as transcatheter aortic valve implantation and, more recently, sutureless valve bioprostheses. For patients with very high surgical risk, transcatheter implantation is becoming the top therapeutic option. However, the percutaneous technique still has major disadvantages including those related to implantation without excision of the diseased native valve without direct view of the annulus, which increases the probability of developing perivalvular leaks and a high percentage of atrioventricular block. Due to the need for aggressive crimping of pericardial layers, there is uncertainty about their long-term durability. A new technique for AVR using sutureless bioprosthesis has recently been developed. The main advantages of this technique are the excellent haemodynamic performance and fast deployment under direct view, thereby avoiding the knotting of surgical stitches, which is especially advantageous in more technically demanding procedures (e.g. minimally invasive surgery, calcified aortic root and reoperations). The good clinical results of these valves have been supported by scientific evidence, making it a feasible option for patients who are candidates for AVR using biologic prosthesis, especially for those with mid-high surgical risk for standard AVR and percutaneous transcatheter valve implantation. In this article, we review the latest evidence on these new prostheses, including their advantages and possible disadvantages.
Subject(s)
Aortic Valve/surgery , Bioprosthesis , Heart Valve Diseases/surgery , Heart Valve Prosthesis Implantation/methods , Heart Valve Prosthesis , Minimally Invasive Surgical Procedures/methods , Sutureless Surgical Procedures/methods , Humans , Prosthesis DesignABSTRACT
Preserving the subvalvular mitral valve apparatus during mitral valve replacement is extremely important to minimize progressive postoperative left ventricular remodeling and dysfunction. We describe a simple and reproducible surgical technique that prevents the complications that can occur after total mitral anterior leaflet preservation.
Subject(s)
Heart Valve Prosthesis Implantation/methods , Mitral Valve/surgery , Ventricular Outflow Obstruction/prevention & control , Bioprosthesis , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/instrumentation , Humans , Mitral Valve/physiopathology , Prosthesis Design , Treatment Outcome , Ventricular Outflow Obstruction/etiology , Ventricular Outflow Obstruction/physiopathologyABSTRACT
UNLABELLED: The long-term results of cryomaze in patients with longstanding persistent atrial fibrillation during concomitant surgical procedures are still uncertain. METHODS: Between 2006 and 2011, 150 consecutive patients with associated long-lasting permanent atrial fibrillation and associated heart disease underwent heart surgery were treated by biatrial Cox-Maze (63 patients) or by isolated endocardial or epicardial left atrial cryoablation (83 patients) concomitantly. The results at 3 years in these groups were compared with clinical monitoring, electrocardiography, 24-hour Holter, and echocardiography with measurement of the transmitral A wave at 1, 6 and 12 months and annually thereafter in all patients. RESULTS: Patients undergoing Cox-Maze IV ablation presented rates of freedom from atrial fibrillation of 97, 94, 89, 80 and 54% at 1, 6, 12, 24 and 36 months, respectively. In the 12-month follow-up, these differences were significant (p<.05). The independent risk factors of atrial fibrillation recurrence was isolated ablation of left atrium. CONCLUSIONS: Atrial fibrillation by cryothermia ablation had a high success rate before 2 years postoperatively. Recurrence of atrial fibrillation increased thereafter regardless of the technique used, although it was more intense and developed earlier in cases of monoatrial ablation. For the treatment of other long-lasting permanent atrial fibrillation cardiac surgery-associated pathology, an aggressive biatrial treatment with Cox maze ablation should be performed.